Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Arck Systems (A), (B), (C), (D), (E) and (F), Teaching Note
Larkin, Ian I.Nota del Instructor HBS-911074-ELiderazgo y Dirección de personasTeaching Note for 911056, 911057, 911058, 911059, 911060 and 911073.Desde 0,00 €
-
Arck Systems (F)
Larkin, Ian I.Caso HBS-911073-ELiderazgo y Dirección de personasThe Arck Systems series of cases describes the dilemmas faced by a senior sales manager in determining a sales compensation plan at an enterprise software company. The existing compensation plan is aggressive and highly rewards "star" performers. The cases track a series of changes the manager makes to the sales compensation plan in response to negative and unintended consequences of the existing system. The cases illustrate the tradeoffs inheren...Desde 5,74 €
-
Arck Systems (E)
Larkin, Ian I.Caso HBS-911060-ELiderazgo y Dirección de personasThe Arck Systems series of cases describes the dilemmas faced by a senior sales manager in determining a sales compensation plan at an enterprise software company. The existing compensation plan is aggressive and highly rewards "star" performers. The cases track a series of changes the manager makes to the sales compensation plan in response to negative and unintended consequences of the existing system. The cases illustrate the tradeoffs inheren...Desde 5,74 €
-
Silic (B): Choosing Cost or Fair Value on Adoption of IFRS
Hawkins, David F.; Dessain, Vincent; Barron, AndrewCaso HBS-108031-EContabilidad y controlSupplements the (A) case.Desde 5,74 €
-
Silic (A): Choosing Cost or Fair Value on Adoption of IFRS
Hawkins, David F.; Dessain, Vincent; Barron, AndrewCaso HBS-108030-EContabilidad y controlA French real estate firm must choose to report its primary asset (investment property) using either cost or fair-value accounting methods upon adoption of international accounting standards (IAS) in 2005.Desde 8,20 €
-
Gucci Group: Freedom within the Framework
Martinez-Jerez, F. Asis; Corsi, Elena; Dessain, VincentCaso HBS-109079-EContabilidad y controlGucci Group's CEO had to decide if his decentralized management style was the most effective philosophy in an economic downturn. The sharing of customer information across units and its use in the creative process are key initiatives analyzed in the case. CEO Robert Polet joined the high-end fashion Gucci Group in 2004, after 26 years at one of the largest consumer goods companies. Since his arrival, the Group had grown both in revenues and profi...Desde 8,20 €
-
Silic (A) and (B): Choosing Cost or Fair Value on Adoption of IFRS, Teaching Note
Dessain, Vincent; Barron, Andrew; Hawkins, David F.; Riedl, Edward J.Nota del Instructor HBS-108078-EContabilidad y controlTeaching Note for 108-030 and 108-031.Desde 0,00 €
-
Grupo Gucci: Libertad dentro de la Estructura
Martinez-Jerez, F. Asis; Corsi, Elena; Dessain, VincentCaso HBS-111S10Contabilidad y controlCEO del Grupo Gucci tuvo que decidir si su estilo de gestión descentralizada era la filosofía más efectiva en una recesión económica. El intercambio de información de los clientes en todas las unidades y su uso en el proceso creativo son iniciativas clave analizados en el caso. CEO Robert Polet se unió al grupo Gucci moda de gama alta en 2004, después de 26 años en una de las mayores empresas de bienes de consumo. Desde su llegada, el Grupo había...Desde 8,20 €
-
Reinventing Brainlab
Herzlinger, Regina E.; Dessain, Vincent; Misztal, KarolCaso HBS-313069-EDirección estratégicaThe management of Germany's Brainlab AG, a leading provider of software-driven oncology and surgery solutions, needs to evaluate strategic options for proceeding without an exclusive hardware partner in its most profitable business segment.Desde 8,20 €
-
Sanofi Pasteur: The Dengue Vaccine Dilemma
Rangan, V. Kasturi; Bloom, David E.; Dessain, Vincent; Billaud, EmilieCaso HBS-514074-EIn 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a good balanced immune answer, it had a proof of efficacy of only 30%, far below the 70% mark the company had targeted. Guillaume Leroy, vice president of the Dengue Company at Sanofi Pa...Desde 8,20 €